CBN (Cannabinol) is a minor cannabinoid found in cannabis. It is a product of the degradation of THC (Delta-9-tetrahydrocannabinol) over time and exposure to light and air. CBN is mildly psychoactive, but its effects are generally considered to be less potent than those of THC.
Related Articles:
Charlotte’s Web Expands R&D with Launch of CW Labs Sciences DivisionTim Orr Joins Charlotte’s Web to Lead Experienced Team on Science, Safety and Innovation in Hemp Phytocannabinoid Research BOULDER, CO, March…Read More
InMed Introduces IntegraSyn™: An Integrated Cannabinoid Manufacturing SystemVANCOUVER, BC, June 24, 2020 /CNW/ – InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (TSX: IN) (OTCQX: IMLFF), a clinical-stage pharmaceutical company…Read More
Pressurized Hot Water ExtractionAs cannabis products become more attainable across the country, concentrates have been making a big name for themselves. With this…Read More
CannabigerolDespite being discovered in 1964 and called the “mother” of all cannabinoids, the “stem cell,” cannabigerol (CBG), has mostly flown…Read More
InMed and Almac Group Developing Improved Cannabinoid Production MethodsVANCOUVER, May 5, 2020 /CNW/ – InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (TSX:IN; OTCQX:IMLFF), a clinical-stage pharmaceutical company developing medications targeting…Read More
Sanobiotec Taps into Potential of Minor CannabinoidsResearch of Cannabis Plant’s Phytochemicals for Progressive Illness Treatment Credit: Sanobiotec Minor cannabinoids have a wide variety of health-beneficial properties, however,…Read More
InMed Announces Completion of Initial Phase 1 Clinical Trial of INM-755 CBN Cream in Healthy SubjectsVANCOUVER, April 1, 2020 /CNW/ – InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (TSX:IN; OTCQX:IMLFF), a clinical stage pharmaceutical company developing medications…Read More
Down to the Last Drop: Squeezing Out More Oil from Industrial HempDuring our 2019 conference Concentration, Frenchy Cannoli provided a passionate keynote seminar in which he called out the cultivation of…Read More
InMed Submits Clinical Trial Application to Evaluate INM-755 in Second Phase 1 TrialVANCOUVER, March 24, 2020 /CNW/ – InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (TSX:IN; OTCQX:IMLFF), a clinical stage pharmaceutical company developing medications…Read More
Geocann is first-to-market introducing cannabigerol (CBG) formulations utilizing the VESIsorb® drug delivery systemCBG is among the many emerging cannabinoids and terpenes that Geocann is committed to pioneering through its technical formulation expertise…Read More
